Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 1, 2015, Pages 23-27

  Fiorentino, Alba ^a   Balducci, Mario ^b   De Bonis, Pasquale ^c   Chiesa, Silvia ^b   De Filippo, Laura ^b   Mangiola, Annunziato ^c   De Rose, Fiorenza ^b   Autorino, Rosa ^b   Rinaldi, Carla ^b   Fersino, Sergio ^b   Diletto, Barbara ^b   Matteucci, Paolo ^b   Ciurlia, Elisa ^b   Fusco, Vincenzo ^a   Anile, Carmelo ^c   Valentini, Vincenzo ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b Department of Radiation Oncology ^*  (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

chemoradiation; comorbidity; elderly; Glioblastoma; temozolomide

Indexed keywords

6 O METHYLGUANINE; ALKYLATING AGENT; DACARBAZINE; DEXAMETHASONE; DNA METHYLTRANSFERASE; DRUG THERAPY; TEMOZOLOMIDE;

ACUTE TOXICITY; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; AGED; AGED HOSPITAL PATIENT; ANALOGS AND DERIVATIVES; ARTICLE; BLOOD TOXICITY; BRAIN NEOPLASMS; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CHEMORADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GERIATRIC DISORDER; GLIOBLASTOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; SOMNOLENCE; STEREOTACTIC CONFORMAL RADIOTHERAPY; SURVIVAL TIME; THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANALOGS AND DERIVATIVES; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHEMORADIOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; METHODS; PATIENT SELECTION; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; THERAPEUTIC USE; THERAPY; TREATMENT OUTCOME;

EID: 84973470134     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182868ea2     Document Type: Article

References (54)

1. Greig NH, Ries LG, Yancik R, et al. Increasing annual incidence of primary malignant brain tumors in elderly. J Natl Cancer Inst. 1990;82:1621-1624.
2. Werner MH, Phuphanich S, Lyman GH, et al. The increasing incidence of primary central nervous system lymphoma in elderly. Cancer. 1995;76:1634-1642.
3. Chargari C, Feuvret L, Bauduceau O, et al. Treatment of elderly patients with glioblastoma: from clinical evidence to molecular highlights. Cancer Treat Rev. 2012;38:988-995.
4. Salford LG, Brun A, Nirfalk S, et al. Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J Neurosurg. 1988;69:506-509.
5. Stupp R, Mason W, Van der Bent M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblatoma. N Engl J Med. 2005;352:987-996.
6. Athanassiou H, Sinodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23:2372-2377.
7. Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol. 2005;74:167-171.
8. Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol. 2002;64:259-273.
9. Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1989;16:1405-1409.
10. De Angelis LM. Brain tumors. N Engl J Med. 2001;344:114-123.
11. Curran WJ Jr., Scott CB, Horton J, et al. Recursive portioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704-710.
12. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26:239-244.
13. Yovino S, Grossman SA. Treatment of glioblastoma in "elderly" patients. Curr Treat Opin Oncol. 2011;12:253-262.
14. Iwamoto FM, Cooper AR, Reiner AS, et al. Glioblastoma in elderly: The Memorial-Sloan Kettering Cancer Center Experience (1997-2007). Cancer. 2009;115:3758-3766.
15. Brandes A, Fiorentino MV. Treatment of high grade gliomas in the elderly. Oncology. 1998;55:1-6.
16. Shikama N, Sasaki S, Shinoda A, et al. Treatment outcome of elderly patients with glioblastoma who received combination therapy. Am J Clin Oncol. 2012;35:486-489.
17. Kimple RJ, Grabowski S, Papez M, et al. Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme? Am J Clin Oncol. 2010;33:265-270.
18. Bucker JC. Factors influencing survival in high grade gliomas. Semin Oncol. 2003;30:10-14.
19. Fiorentino A, Caivano R, Chiumento C, et al. Comorbidity assessment and adjuvant radiochemotherapy in elderly affected by glioblastoma. Med Oncol. 2012;29:3467-3471.
20. Balducci M, Fiorentino A, De Bonis P, et al. Impact of age and comorbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies. Med Oncol. 2012;29:3478-3483.
21. Fiorentino A, Balducci M, Chiesa S, et al. Elderly people with glioblastoma. Lancet Oncol. 2012;13:e327-e328.
22. Balducci M, Apicella G, Manfrida S, et al. Single-Arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high grade gliomas. Strahlen Onkol. 2010;186:558-564.
23. Balducci M, D'Agostino GR, Manfrida S, et al. Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study. J Neuro Oncol. 2010;97:95-100.
24. D'Agostino GR, Balducci M, Anile C, et al. An analysis of two different schedules of radiochemotherapy with concomitant temozolomide in high grade gliomas. Proc Am Soc Clin Oncol. 2007;25:A2035.
25. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
26. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21:109-122.
27. Lawrence YR, Li XA, el Naqa I, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys. 2010;76(suppl): S20-S27.
28. Laigle-Donadey F, Delattre JY. Glioma in elderly. Curr Opin Oncol. 2006;18:644-647.
29. Lamborn KR, Chang SM, Prados MD, et al. Prognostic factor for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004;6:227-235.
30. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24:2563-2569.
31. Kelly PJ, Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery. 1994; 34:62-66.
32. Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people: a randomized study. Acta Neurochir. 2003;145:5-10.
33. Keim-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in elderly. N Engl J Med. 2007;356:1527-1535.
34. Mohan DS, Suh JH, Phan JL, et al. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys. 1998;42:981-987.
35. Villa S, Bertoni F, Bossi A, et al. Efficacy of radiotherapy for malignant gliomas in elderly patients. Int J Radiat Oncol Biol Phys. 1998;42:977-980.
36. Glantz M, Chamberlain M, Liu Q, et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer. 2003;97:2262-2266.
37. Roa W, Brasher PMA, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22: 1583-1588.
38. Minniti G, Lanzetta G, Scaringi C, et al. Phase II study of shortcourse radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2012;83:93-99.
39. Chamberlain MC, Chalmers L. A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol. 2007;82:207-209.
40. Chinot OL, Barrie M, Frauger E, et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population. Cancer. 2004;100:2208-2214.
41. Wick W, Platten M, Meisner C, et al. For the NOA-08 Study Group of the Neuro-oncology Working Group (NOA) of the German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707-715.
42. Malmstrom A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13: 916-926.
43. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
44. Brandes A, Vastola F, Basso U, et al. A prospective study on glioblastoma in elderly. Cancer. 2003;97:657-660.
45. Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008;88:97-110.
46. Fiorica F, Berretta M, Colosimo C, et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. Arch Gerontol Geriatr. 2010;51:277-282.
47. Gerstein J, Franz K, Steinbach JP, et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol. 2010;97:382-386.
48. Fiorentino A, Chiumento C, Caivano R, et al. Adjuvant radiochemotherapy in the elderly affected by glioblastoma: singleinstitution experience and literature review. Radiol Med. 2012. Doi: 10.1007/S11547-012-0906-7.
49. Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro Oncol. 2011;13:428-436.
50. Simon TG, Beland MD, Machan JT, et al. Charlson Comorbidity Index predicts patients outcome in cases of inoperable non-small cell lung cancer treated with radiofrequency ablation. Eur J Radiol. 2012;81:4167-4172.
51. Berglund A, Wigertz A, Adolfsson J, et al. Impact of comorbidity on management and mortality in women diagnosed with breast cancer. Breast Cancer Res Treat. 2012;135:281-289.
52. Gomez-Millan J. Radiation therapy in the elderly: more side effects and complications? Crit Rev Oncol Hematol. 2009;71: 70-78.
53. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
54. Brandes A, Franceschi E, Tosoni A, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer. 2009;115:3512-3518.